1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Vinogradova, O. Haas, T. Plow, E.F. Qin, J. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic 1 90.00 90.00 90.00 1.000 1.000 1.000 C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C4 H7 N O4 133.103 y ASPARTIC ACID L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking US Proc.Natl.Acad.Sci.USA PNASA6 0040 0027-8424 97 1450 1455 10.1073/pnas.040548197 10677482 A structural basis for integrin activation by the cytoplasmic tail of the alpha IIb-subunit. 2000 10.2210/pdb1dpq/pdb pdb_00001dpq 1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 2343.505 INTEGRIN ALPHA-IIB SUBUNIT CYTOPLASMIC DOMAIN P1029A/P1030A 1 syn polymer no no KVGFFKRNRAALEEDDEEGE KVGFFKRNRAALEEDDEEGE A polypeptide(L) n n n n n n n n n n n n n n n n n n n n database_2 pdbx_nmr_exptl_sample_conditions pdbx_nmr_software pdbx_struct_assembly pdbx_struct_oper_list struct_ref_seq_dif repository Initial release Version format compliance Version format compliance Data collection Database references Derived calculations Experimental preparation 1 0 2000-02-28 1 1 2008-04-27 1 2 2011-07-13 1 3 2021-11-03 _database_2.pdbx_DOI _database_2.pdbx_database_accession _pdbx_nmr_exptl_sample_conditions.pressure_units _pdbx_nmr_software.name _struct_ref_seq_dif.details SOLUTION STRUCTURE OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN RCSB Y RCSB 1999-12-27 REL THE PEPTIDE WAS CHEMICALLY SYNTHESIZED. THE SEQUENCE OF RESIDUES IS NATURALLY FOUND IN THE PLATELETS OF HOMO SAPIENS (HUMAN). sample DEUT. DPC(DODECYL-PHOSPHOCHOLINE) MICELLES USED back calculated data agree with experimental NOESY spectrum 30 11 2D NOESY DQF-COSY 2D TOCSY 50 mM NACL 5.0 1 atm 298 K simulated annealing 1 minimized average structure 3 MM PEPTIDE VARIAN collection VNMR 5.5 DELAGIO, F. processing NMRPipe GARRETT, D.S. data analysis PIPP BRUNGER, A.T. structure solution X-PLOR 3.2 BRUNGER, A.T. refinement X-PLOR 3.2 500 Varian INOVA LYS 1 n 1 LYS 1 A VAL 2 n 2 VAL 2 A GLY 3 n 3 GLY 3 A PHE 4 n 4 PHE 4 A PHE 5 n 5 PHE 5 A LYS 6 n 6 LYS 6 A ARG 7 n 7 ARG 7 A ASN 8 n 8 ASN 8 A ARG 9 n 9 ARG 9 A ALA 10 n 10 ALA 10 A ALA 11 n 11 ALA 11 A LEU 12 n 12 LEU 12 A GLU 13 n 13 GLU 13 A GLU 14 n 14 GLU 14 A ASP 15 n 15 ASP 15 A ASP 16 n 16 ASP 16 A GLU 17 n 17 GLU 17 A GLU 18 n 18 GLU 18 A GLY 19 n 19 GLY 19 A GLU 20 n 20 GLU 20 A author_defined_assembly 1 monomeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 identity operation 0.0000000000 0.0000000000 0.0000000000 1 A A O H GLU ASP 14 16 1.54 2 A A O H GLU ASP 14 16 1.53 3 A A O H ASP GLU 16 20 1.54 3 A A O H GLU ASP 14 16 1.57 4 A A O H GLU ASP 14 16 1.55 8 A A O H GLU ASP 14 16 1.49 1 A VAL 2 34.33 47.38 1 A ARG 9 -57.42 -9.19 1 A LEU 12 72.60 41.72 1 A ASP 15 -68.20 53.15 1 A ASP 16 -69.77 38.53 2 A VAL 2 34.38 46.28 2 A ARG 9 -53.98 -8.11 2 A LEU 12 80.35 40.18 2 A ASP 15 -68.10 50.83 2 A ASP 16 -70.08 37.93 3 A VAL 2 23.22 48.49 3 A ARG 9 -53.00 -8.08 3 A LEU 12 81.13 40.26 3 A ASP 15 -67.14 60.31 3 A ASP 16 -70.84 36.79 4 A VAL 2 34.21 46.92 4 A ARG 9 -58.24 -7.77 4 A LEU 12 79.92 40.10 4 A ASP 15 -66.18 60.27 4 A ASP 16 -70.50 37.92 5 A VAL 2 22.00 51.45 5 A ARG 9 -51.63 -8.82 5 A LEU 12 73.12 41.30 5 A ASP 16 -70.32 38.53 6 A VAL 2 34.21 47.56 6 A ARG 9 -53.24 -8.40 6 A LEU 12 115.32 23.56 6 A GLU 13 78.37 37.19 6 A ASP 16 -70.48 39.24 7 A VAL 2 33.99 47.09 7 A ARG 9 -52.94 -9.05 7 A LEU 12 73.29 41.46 7 A GLU 14 -46.03 -71.12 7 A ASP 15 -65.62 67.24 7 A ASP 16 -71.67 36.01 8 A VAL 2 23.14 48.28 8 A ARG 9 -55.35 -6.83 8 A LEU 12 83.00 40.98 8 A ASP 15 -66.51 50.83 8 A ASP 16 -71.71 39.87 9 A VAL 2 22.88 48.76 9 A ARG 9 -54.84 -8.88 9 A LEU 12 70.69 40.65 9 A GLU 14 -56.15 -84.85 9 A ASP 16 -73.93 28.30 10 A VAL 2 34.02 47.76 10 A ARG 9 -58.69 -8.82 10 A LEU 12 72.82 40.91 10 A ASP 15 45.68 71.44 10 A ASP 16 -142.77 31.14 11 A VAL 2 34.25 47.21 11 A ARG 9 -55.26 -6.78 11 A LEU 12 115.31 22.30 11 A GLU 13 80.80 36.54 11 A ASP 16 -71.85 38.98 minimized average SOLUTION STRUCTURE OF THE CONSTITUTIVELY ACTIVE MUTANT OF THE INTEGRIN ALPHA IIB CYTOPLASMIC DOMAIN. 1 N N A VAL 2 A VAL 2 HELX_P A ALA 10 A ALA 10 1 1 9 CELL ADHESION HELIX, CELL ADHESION ITA2B_HUMAN UNP 1 P08514 1020 1039 1DPQ 1 20 P08514 A 1 1 20 1 PRO engineered mutation ALA 10 1DPQ A P08514 UNP 1029 10 1 PRO engineered mutation ALA 11 1DPQ A P08514 UNP 1030 11 1 P 1